Novogene Co., Ltd. (SHA:688315)
China · Delayed Price · Currency is CNY 15.28
-0.36 (-2.30%)
At close: Feb 13, 2026
Novogene Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,166 | 2,104 | 1,998 | 1,925 | 1,864 | 1,488 |
Other Revenue | 7.11 | 7.11 | 4.61 | 0.86 | 2.73 | 2.19 |
| 2,173 | 2,111 | 2,002 | 1,926 | 1,866 | 1,490 | |
Revenue Growth (YoY) | 3.85% | 5.46% | 3.97% | 3.17% | 25.26% | -2.92% |
Cost of Revenue | 1,241 | 1,194 | 1,150 | 1,077 | 1,072 | 972.44 |
Gross Profit | 932.2 | 917.55 | 852.43 | 849.07 | 793.9 | 517.59 |
Selling, General & Admin | 579.29 | 564.3 | 556.7 | 503.88 | 423.81 | 361.97 |
Research & Development | 167.44 | 131.45 | 124.18 | 125.57 | 145.29 | 112.31 |
Other Operating Expenses | 2.79 | 3.69 | -21.05 | -8.7 | -25.3 | 2.64 |
Operating Expenses | 774.57 | 721.99 | 675.46 | 648.03 | 563.57 | 483.96 |
Operating Income | 157.63 | 195.57 | 176.97 | 201.04 | 230.33 | 33.62 |
Interest Expense | -1.62 | -1.3 | -2.13 | -2.15 | -2.92 | -10.27 |
Interest & Investment Income | 30.22 | 31.41 | 27.47 | 11.89 | 8.27 | 3.71 |
Currency Exchange Gain (Loss) | 2.61 | 2.61 | 13.21 | 11.78 | -6.47 | -7.17 |
Other Non Operating Income (Expenses) | 9.75 | -0.94 | -2.31 | -4.36 | -2.72 | -2.42 |
EBT Excluding Unusual Items | 198.6 | 227.35 | 213.22 | 218.21 | 226.49 | 17.47 |
Gain (Loss) on Sale of Investments | 13.18 | 14.46 | -2.25 | -6.39 | 23.33 | 3.04 |
Gain (Loss) on Sale of Assets | -1.99 | -2.08 | -2.31 | -5.3 | -3.58 | -2.3 |
Asset Writedown | -6.13 | -9.15 | - | -8.46 | 0.03 | - |
Other Unusual Items | -6.21 | -5.86 | 3.98 | 10.51 | 0.18 | 17.32 |
Pretax Income | 197.45 | 224.73 | 212.63 | 208.56 | 246.46 | 35.53 |
Income Tax Expense | 17.85 | 20.89 | 29.41 | 27.02 | 17.58 | 1.09 |
Earnings From Continuing Operations | 179.6 | 203.84 | 183.22 | 181.53 | 228.89 | 34.44 |
Minority Interest in Earnings | -4.39 | -7.05 | -5.17 | -4.3 | -3.69 | 2.1 |
Net Income | 175.21 | 196.79 | 178.06 | 177.23 | 225.2 | 36.54 |
Net Income to Common | 175.21 | 196.79 | 178.06 | 177.23 | 225.2 | 36.54 |
Net Income Growth | -6.42% | 10.52% | 0.47% | -21.30% | 516.32% | -68.03% |
Shares Outstanding (Basic) | 407 | 410 | 405 | 403 | 387 | 365 |
Shares Outstanding (Diluted) | 407 | 410 | 405 | 403 | 387 | 365 |
Shares Change (YoY) | -0.11% | 1.31% | 0.47% | 4.14% | 5.86% | 2.31% |
EPS (Basic) | 0.43 | 0.48 | 0.44 | 0.44 | 0.58 | 0.10 |
EPS (Diluted) | 0.43 | 0.48 | 0.44 | 0.44 | 0.58 | 0.10 |
EPS Growth | -6.33% | 9.09% | - | -24.14% | 480.00% | -68.75% |
Free Cash Flow | 144.44 | 202.97 | 217.5 | 86.73 | 181.47 | 250 |
Free Cash Flow Per Share | 0.35 | 0.49 | 0.54 | 0.21 | 0.47 | 0.68 |
Dividend Per Share | 0.050 | 0.050 | 0.048 | 0.047 | 0.060 | - |
Dividend Growth | 5.26% | 5.26% | 1.06% | -21.67% | - | - |
Gross Margin | 42.90% | 43.46% | 42.58% | 44.09% | 42.54% | 34.74% |
Operating Margin | 7.25% | 9.26% | 8.84% | 10.44% | 12.34% | 2.26% |
Profit Margin | 8.06% | 9.32% | 8.89% | 9.20% | 12.07% | 2.45% |
Free Cash Flow Margin | 6.65% | 9.61% | 10.86% | 4.50% | 9.72% | 16.78% |
EBITDA | 294.04 | 328.13 | 304.4 | 313.1 | 347.24 | 140.26 |
EBITDA Margin | 13.53% | 15.54% | 15.20% | 16.26% | 18.61% | 9.41% |
D&A For EBITDA | 136.41 | 132.56 | 127.43 | 112.05 | 116.91 | 106.64 |
EBIT | 157.63 | 195.57 | 176.97 | 201.04 | 230.33 | 33.62 |
EBIT Margin | 7.25% | 9.26% | 8.84% | 10.44% | 12.34% | 2.26% |
Effective Tax Rate | 9.04% | 9.30% | 13.83% | 12.96% | 7.13% | 3.07% |
Revenue as Reported | 2,173 | 2,111 | 2,002 | 1,926 | 1,866 | 1,490 |
Advertising Expenses | - | 68.06 | 59.97 | 28.59 | 20.02 | 10.8 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.